Responses
Rheumatology
Protocol
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
Compose a Response to This Article
Other responses
No responses have been published for this article.